Mutation-based circulating tumor DNA detection approach to monitoring the therapy response in breast cancer

Liu, Jiaqi; Huang, Yansong; Wang, Xiang

doi:10.1016/j.jncc.2023.08.006

Journal of the National Cancer Center

2023

DOI: 10.1016/j.jncc.2023.08.006

|View full text |Cite

Mutation-based circulating tumor DNA detection approach to monitoring the therapy response in breast cancer

Jiaqi Liu,

Yansong Huang,

Xiang Wang

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 10 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response

Liu,

Li,

Tang

et al. 2024

Preprint

View full text Add to dashboard Cite

The fragmentomics-based cell-free DNA (cfDNA) assays have recently demonstrated remarkable capabilities in identifying various cancers from non-conditional healthy controls. However, their accuracy in differentiating early-stage cancers from benign lesions, especially with inconclusive imaging results, remains unclear. In breast cancer, imaging-based screening methods often yield high false-positive rates, particularly in women with breast nodules, leading to unnecessary biopsies and increasing patient discomfort and healthcare burden. In this multi-center study, we enrolled 560 female participants and showed that cfDNA fragmentomics, using whole-genome sequencing, is a strong non-invasive biomarker for breast cancer. Among various cfDNA fragmentomics profiles, the fragment size ratio (FSR), fragment size distribution (FSD), and copy number variation (CNV) exhibited superior distinguishing ability compared to Griffin, motif breakpoint (MBP), and neomer features. Our cfDNA fragmentomics (cfFrag) model, which incorporates the three optimal fragmentomics features, successfully discriminated early-stage breast cancers from benign nodules, even at a low sequencing depth (3x). Notably, it demonstrated a specificity of 94.1% in asymptomatic healthy women at a 90% sensitivity for breast cancer. Furthermore, we highlight the clinical utility of the cfFrag model in predicting patient responses to neoadjuvant chemotherapy (NAC), and its integration with multimodal features, including radiological results and cfDNA methylation features, achieved high AUC values of 0.93-0.94 and 0.96, respectively.

show abstract

Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response

Liu,

Li,

Tang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Mutation-based circulating tumor DNA detection approach to monitoring the therapy response in breast cancer

Cited by 1 publication

References 10 publications

Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response

Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response

Contact Info

Product

Resources

About